|Bid||0.00 x 1400|
|Ask||0.00 x 900|
|Day's Range||21.34 - 21.49|
|52 Week Range||19.92 - 25.18|
|PE Ratio (TTM)||37.56|
|Forward Dividend & Yield||0.46 (2.16%)|
|1y Target Est||24.25|
Engineers in both the energy and biotech sectors are among top earners, surpassing Wall Street. Yahoo Finance's Seana Smith, Jennifer Rogers and Pras Subramanian discuss.
This analysis is intended to introduce important early concepts to people who are starting to invest and want a simplistic look at the return on Grifols SA (BME:GRF) stock. WithRead More...
On Thursday, June 21, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Thursday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Grifols S.A. (NASDAQ: GRFS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), and ImmunoGen Inc. (NASDAQ: IMGN).
- Grifols Procleix Ultrio Elite assay screens for HIV-1, HCV, and HBV and detects HIV-2; the Procleix WNV assay screens for West Nile virus - Both assays are approved to run on the fully automated NAT ...
Biotech stocks represent a peculiar conundrum. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. Thus, creating a list of biotech stocks to buy will always be a tough challenge.
NEW YORK, June 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Eldorado ...
BARCELONA, Spain, May 31, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), one of the leading companies in the world in plasma-derived biological medicines and transfusion medicine, today announced it is adding a Daratumumab neutralization testing service to its extensive menu of services offered at Grifols Immunohematology Center laboratory (San Marcos, Texas). This new test facilitates complete antibody screening and identification in pretransfusion testing of patients under this therapy.
- Grifols conventional antisera reagents recently received licensing approval by the U.S. Food & Drug Administration for manual testing in immunohematology laboratories - The addition of antisera reagents ...
May 10 (Reuters) - Boya Bio-Pharmaceutical Group Co Ltd : * SAYS IT SIGNS AGREEMENT WITH GRIFOLS S.A. TO SET UP BLOOD PLASMA STATIONS WITH INITIAL INVESTMENT AT ABOUT 50 MILLION EUROS ($59.30 million) ...
Grifols and Novo Nordisk are expanding in the Triangle, and so is the training center that produces talent for the biomanufacturing giants.
BARCELONA, Spain, April 16, 2018 /PRNewswire/ -- Today, Grifols, S.A. (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced it has donated over 25 million international units (IU) of blood clotting factor medicines over the last year. This donation is part of Grifols' commitment to provide a minimum of 200M IU to the World Federation of Hemophilia (WFH) Humanitarian Aid Program over eight years starting in 2014. An estimated 400,000 people around the world have hemophilia, yet only 25% receive adequate treatment.
Today I will examine Grifols SA.’s (BME:GRF) latest earnings update (31 December 2017) and compare these figures against its performance over the past couple of years, in addition to howRead More...
BARCELONA, Spain , April 6, 2018 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced that it has filed its 2017 Annual Report on Form 20-F with the United ...
In this article I am going to calculate the intrinsic value of Grifols SA. (BME:GRF) using the discounted cash flows (DCF) model. If you want to learn more about thisRead More...
Grifols SA. (BME:GRF) is trading with a trailing P/E of 23.2x, which is lower than the industry average of 28.5x. While this makes GRF appear like a great stock toRead More...
Grifols SA. (BME:GRF) delivered an ROE of 18.20% over the past 12 months, which is an impressive feat relative to its industry average of 17.90% during the same period. WhileRead More...
Barcelona, Spain-based health care product and solutions giant Grifols has broken ground on a new $120 million facility at its Johnston County site, part of a $320 million investment in Clayton by 2022. The company's latest 150,000-square-foot addition in Clayton – expected to debut in 2022 – will be a purification and filling facility, used for making hemotherapy products, according to Grifols. Juan Antonio Garcia Diaz, president of Grifols Therapeutics LLC, called the facility "crucial to Grifols’ expansion plans at the Clayton site.
Barcelona, Spain-based health care product and solutions giant Grifols has broken ground on a new $120 million facility at its Johnston County site as it plans to invest another $320 million in Clayton by 2022.
We expect Henry Schien's (HSIC) partnership with Grifols to be strategically accretive to its portfolio given the rising demand for saline products in U.S. market.
- The FDA approval received in 2017 allows Grifols to market its Normal Saline solution in 500mL polypropylene bags in the U.S. to mitigate the current shortage of Normal Saline in this market - This agreement ...
Alpha-1 is often overshadowed by patients' smoking history, even though guidelines from the World Health Organization, the American Thoracic Society, and the COPD Foundation recommend testing all people with COPD for alpha-1, regardless of their age or smoking history. "Alpha-1 is a debilitating rare disease that is often overlooked," said Bill Zabel, President, Grifols North America Sales and Commercial Operations.
BARCELONA, Spain, Feb. 6, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and immune globulin products for patients, has received approval from the U.S. Food & Drug Administration (FDA) for a new higher potency formulation of its HyperRAB® rabies immune globulin [human] for rabies postexposure prophylaxis (treatment of a person immediately after exposure to the rabies virus). The new formulation is twice the potency (300 IU/mL) of currently available rabies immune globulin options, offering a greater concentration of anti-rabies virus antibodies within each mL of volume, and for patients, the potential for fewer injections by significantly reducing the volume of medication administered in each dose.
Grifols shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.